REG - Novacyt S.A. - Operational Update

Novacyt SAAnnouncement

Mon 09:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260601:nRSA4341Ga&default-theme=true

RNS Number : 4341G  Novacyt S.A.  01 June 2026

The information contained within this announcement is deemed by Novacyt S.A.
to constitute inside information as stipulated under the Market Abuse
Regulations (EU) No. 596/2014. Upon the publication of this announcement via
Regulatory Information Service, this inside information is now considered to
be in the public domain.

 

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Operational Update

 

Paris, France, and Manchester, UK - 1 June 2026 Novacyt S.A. (EURONEXT
GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company
with a broad portfolio of integrated technologies and services, announces
further proposed changes to its operating cost base.

 

Following the successful launch of a number of new products over the past 18
months and the recent acquisition of Southern Cross Diagnostics Pty Ltd, the
Group is accelerating its plans to focus and streamline its operations and
cost base.

 

The Company announces that it has begun a consultation process with certain
members of staff across the Group which may result in a reduction of up to 40%
in the Group's headcount (total headcount as at 26 May 2026 was circa 230). A
further announcement will be released in respect of the outcome of the
consultation process in due course.

 

Should the restructuring proceed, the associated labour and non-labour savings
are expected to reduce the Group's annual cash burn by up to circa £4.0m,
once all restructuring initiatives are complete. A cash restructuring charge
of up to circa £1.0m is expected to be incurred. These numbers are
conditional on the consultation process and assume the total reduction of 40%.

 

Contacts

 

 Novacyt SA                                                                https://novacyt.com/investors (https://novacyt.com/investors/)
 Lyn Rees, Chief Executive Officer                                          Via Walbrook PR
 Steve Gibson, Chief Financial Officer                                      

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                                       +44 (0)20 3470 0470
 Matthew Johnson / Charlie Bouverat (Corporate Finance)                                                               

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Singer Capital Markets (Joint Broker)                                                                               +44 (0) 20 7496 3000
 Phil Davies / James Fischer / Samed Ethemi                                                                           
                                                                                                                      
 Allegra Finance (French Listing Sponsor)         +33 (1) 42 22 10 10

                                               r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com)
 Rémi Durgetto / Yannick Petit                    / y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)
  
 Walbrook PR (Financial PR & IR)                                           +44 (0)20 7933 8780 or novacyt@walbrookpr.com (mailto:novacyt@walbrookpr.com)

 Paul McManus / Lianne Applegarth

                                                                         +44 (0)7980 541 893 / +44 (0)7584 391 303
 Alice Woodings

                                                                            +44 (0)7407 804 654

 

 

About Novacyt Group (www.novacyt.com (http://www.novacyt.com/) )

Novacyt is an international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions from sample
to result across multiple sectors including human health, animal health and
environmental.

 

The Company is divided into three business segments:

 Clinical                 Broad portfolio of human clinical in vitro diagnostic products, workflows
                          and services focused on three therapeutic areas:

                          ·      Reproductive Health: NIPT, Cystic Fibrosis and other rapid
                          aneuploidy tests

                          ·      Precision Medicine: DPYD genotyping assay

                          ·      Infectious Diseases: Winterplex, multiplex winter respiratory PCR
                          panel

 Instrumentation          Portfolio of next generation size selection DNA sample preparation platforms
                          and rapid PCR machines, including:

                          ·   Ranger® Technology: automated DNA sample preparation and target
                          enrichment technology

                          ·      genesig q16 and q32 real-time quantitative PCR (qPCR)
                          instruments

 Research Use Only        Range of services for the life sciences industry:

                          ·  Design, manufacture, and supply of high-performance qPCR assays and
                          workflows for use in human health, agriculture, veterinary and environmental,
                          to support global health organisations and the research industry

                          ·   Pharmaceutical research services: whole genome sequencing (WGS) / whole
                          exome sequencing (WES)

 

Novacyt is headquartered in Le Vésinet in France with offices in the UK
(Manchester), Singapore, the US and Canada and has a commercial presence in
over 65 countries, including Australia, following the recent acquisition of
Southern Cross Diagnostics in March 2026, which has opened new distribution
channels to the life sciences and diagnostics industries in the territory and
the wider Asia-Pacific region.

 

The Company is listed on the London Stock Exchange's AIM market ("NCYT") and
on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUAUWRNAUNRRR



            Copyright 2019 Regulatory News Service, all rights reserved